Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have received an average rating of “Hold” from the six research firms that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $19.50.

TAK has been the subject of several research analyst reports. ValuEngine upgraded shares of Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. Zacks Investment Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, Cowen initiated coverage on shares of Takeda Pharmaceutical in a research report on Friday, November 1st. They set a “market perform” rating and a $19.50 price target for the company.

Shares of Takeda Pharmaceutical stock traded down $0.22 during trading hours on Friday, reaching $19.44. The stock had a trading volume of 1,141,500 shares, compared to its average volume of 1,225,027. The stock’s 50 day moving average is $19.85 and its 200 day moving average is $18.67. The firm has a market capitalization of $61.31 billion, a PE ratio of 74.77 and a beta of 0.89. Takeda Pharmaceutical has a twelve month low of $16.10 and a twelve month high of $21.61. The company has a current ratio of 1.18, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.53 earnings per share for the quarter. The business had revenue of $7.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 2.25% and a return on equity of 13.17%. As a group, sell-side analysts predict that Takeda Pharmaceutical will post 1.85 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Adelphi Capital LLP raised its position in shares of Takeda Pharmaceutical by 13.4% during the 3rd quarter. Adelphi Capital LLP now owns 8,991,290 shares of the company’s stock worth $154,650,000 after purchasing an additional 1,060,174 shares during the last quarter. Mondrian Investment Partners LTD boosted its holdings in shares of Takeda Pharmaceutical by 6.7% in the third quarter. Mondrian Investment Partners LTD now owns 3,639,170 shares of the company’s stock valued at $61,866,000 after acquiring an additional 229,000 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Takeda Pharmaceutical by 15.0% in the third quarter. Parametric Portfolio Associates LLC now owns 3,158,924 shares of the company’s stock valued at $54,333,000 after acquiring an additional 411,338 shares in the last quarter. First Trust Advisors LP boosted its holdings in shares of Takeda Pharmaceutical by 23.3% in the third quarter. First Trust Advisors LP now owns 2,041,133 shares of the company’s stock valued at $35,107,000 after acquiring an additional 385,573 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Takeda Pharmaceutical by 17.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,008,189 shares of the company’s stock valued at $39,622,000 after acquiring an additional 303,789 shares in the last quarter. Hedge funds and other institutional investors own 4.57% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Story: How can investors invest in the S&P/TSX Index?

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.